 Michelle Barron
Concepts (265)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 5 | 2022 | 498 | 0.850 |
Why?
| | Hemorrhagic Fever, Ebola | 2 | 2015 | 33 | 0.610 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2016 | 139 | 0.610 |
Why?
| | Hospitalization | 13 | 2024 | 1764 | 0.570 |
Why?
| | Influenza, Human | 5 | 2022 | 549 | 0.540 |
Why?
| | Vaccines, Inactivated | 1 | 2016 | 68 | 0.540 |
Why?
| | Vaccines, Attenuated | 1 | 2016 | 113 | 0.530 |
Why?
| | Viremia | 2 | 2009 | 122 | 0.530 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 28 | 0.490 |
Why?
| | Staphylococcal Infections | 6 | 2020 | 338 | 0.460 |
Why?
| | Antifungal Agents | 9 | 2020 | 134 | 0.430 |
Why?
| | Antibodies, Viral | 1 | 2016 | 527 | 0.430 |
Why?
| | Ambulatory Care | 5 | 2022 | 479 | 0.420 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2009 | 524 | 0.410 |
Why?
| | Dendritic Cells | 2 | 2006 | 438 | 0.390 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 386 | 0.370 |
Why?
| | Bacteremia | 3 | 2020 | 159 | 0.370 |
Why?
| | Adult | 32 | 2024 | 30814 | 0.360 |
Why?
| | Serotonin Syndrome | 1 | 2010 | 5 | 0.350 |
Why?
| | Oxazolidinones | 1 | 2010 | 13 | 0.350 |
Why?
| | Acetamides | 1 | 2010 | 25 | 0.350 |
Why?
| | Methicillin | 1 | 2009 | 11 | 0.330 |
Why?
| | HIV-1 | 2 | 2006 | 771 | 0.330 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2020 | 193 | 0.320 |
Why?
| | Adaptive Immunity | 1 | 2009 | 157 | 0.320 |
Why?
| | Middle Aged | 27 | 2024 | 27078 | 0.310 |
Why?
| | Platelet Transfusion | 1 | 2009 | 63 | 0.310 |
Why?
| | Immunization, Secondary | 3 | 2022 | 82 | 0.300 |
Why?
| | Cytomegalovirus Infections | 1 | 2009 | 181 | 0.300 |
Why?
| | Anti-Infective Agents | 1 | 2010 | 225 | 0.290 |
Why?
| | Immunocompromised Host | 4 | 2024 | 197 | 0.280 |
Why?
| | Vitamin K Deficiency | 1 | 2006 | 10 | 0.270 |
Why?
| | AIDS Vaccines | 1 | 2006 | 41 | 0.270 |
Why?
| | Humans | 50 | 2024 | 115859 | 0.270 |
Why?
| | Blood Platelets | 1 | 2009 | 350 | 0.260 |
Why?
| | Rhizopus | 1 | 2005 | 5 | 0.250 |
Why?
| | Facial Pain | 1 | 2005 | 12 | 0.250 |
Why?
| | Mucormycosis | 1 | 2005 | 20 | 0.250 |
Why?
| | Cross Infection | 3 | 2014 | 202 | 0.250 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 124 | 0.240 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 241 | 0.240 |
Why?
| | Aged | 21 | 2024 | 19292 | 0.240 |
Why?
| | Carbapenems | 2 | 2014 | 16 | 0.240 |
Why?
| | Klebsiella Infections | 2 | 2014 | 23 | 0.230 |
Why?
| | beta-Lactamases | 2 | 2014 | 26 | 0.230 |
Why?
| | Immunity, Innate | 1 | 2009 | 735 | 0.230 |
Why?
| | Klebsiella pneumoniae | 2 | 2014 | 41 | 0.230 |
Why?
| | Chaetomium | 1 | 2003 | 3 | 0.230 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 397 | 0.230 |
Why?
| | Mycoses | 1 | 2003 | 67 | 0.220 |
Why?
| | Male | 27 | 2023 | 56103 | 0.220 |
Why?
| | Sinusitis | 1 | 2005 | 175 | 0.210 |
Why?
| | Female | 28 | 2023 | 60070 | 0.210 |
Why?
| | Candidiasis, Invasive | 2 | 2014 | 5 | 0.210 |
Why?
| | Brain Diseases | 1 | 2003 | 127 | 0.210 |
Why?
| | Saccharomyces cerevisiae | 1 | 2006 | 482 | 0.210 |
Why?
| | Viral Vaccines | 1 | 2023 | 89 | 0.200 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2002 | 221 | 0.190 |
Why?
| | Lung Transplantation | 2 | 2013 | 246 | 0.190 |
Why?
| | Intensive Care Units | 5 | 2021 | 624 | 0.180 |
Why?
| | Case-Control Studies | 7 | 2023 | 3054 | 0.180 |
Why?
| | Pericarditis | 1 | 2020 | 9 | 0.180 |
Why?
| | Organ Transplantation | 3 | 2020 | 161 | 0.180 |
Why?
| | Cryptococcus neoformans | 1 | 2020 | 18 | 0.180 |
Why?
| | Cryptococcosis | 1 | 2020 | 23 | 0.180 |
Why?
| | Zygomycosis | 2 | 2009 | 6 | 0.170 |
Why?
| | United States | 11 | 2023 | 12319 | 0.160 |
Why?
| | Nafcillin | 1 | 2018 | 3 | 0.160 |
Why?
| | Aged, 80 and over | 8 | 2022 | 6434 | 0.160 |
Why?
| | Adolescent | 12 | 2024 | 17935 | 0.160 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 289 | 0.160 |
Why?
| | Cefazolin | 1 | 2018 | 18 | 0.160 |
Why?
| | Pneumonia | 1 | 2024 | 576 | 0.160 |
Why?
| | Emergency Service, Hospital | 6 | 2023 | 1842 | 0.150 |
Why?
| | Disease Outbreaks | 3 | 2015 | 308 | 0.150 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2016 | 37 | 0.140 |
Why?
| | Anti-Bacterial Agents | 4 | 2020 | 1486 | 0.140 |
Why?
| | Echinocandins | 2 | 2014 | 8 | 0.140 |
Why?
| | Young Adult | 10 | 2022 | 10508 | 0.140 |
Why?
| | North America | 1 | 2016 | 263 | 0.130 |
Why?
| | Spores, Bacterial | 1 | 2015 | 19 | 0.130 |
Why?
| | RNA, Messenger | 4 | 2023 | 2581 | 0.130 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 25 | 0.130 |
Why?
| | Containment of Biohazards | 1 | 2015 | 10 | 0.130 |
Why?
| | Treatment Outcome | 9 | 2020 | 9163 | 0.120 |
Why?
| | Population Surveillance | 2 | 2015 | 395 | 0.120 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2015 | 21 | 0.120 |
Why?
| | Coinfection | 1 | 2016 | 120 | 0.120 |
Why?
| | Renal Replacement Therapy | 1 | 2015 | 68 | 0.120 |
Why?
| | Antibodies, Neutralizing | 1 | 2016 | 223 | 0.120 |
Why?
| | Microbial Sensitivity Tests | 3 | 2020 | 299 | 0.120 |
Why?
| | Critical Care | 2 | 2016 | 480 | 0.120 |
Why?
| | Heart Transplantation | 1 | 2020 | 671 | 0.120 |
Why?
| | Bacterial Infections | 1 | 2016 | 222 | 0.120 |
Why?
| | Pulmonary Aspergillosis | 1 | 2013 | 3 | 0.110 |
Why?
| | Virus Diseases | 1 | 2016 | 200 | 0.110 |
Why?
| | Secondary Prevention | 1 | 2015 | 223 | 0.110 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.110 |
Why?
| | Risk Factors | 8 | 2024 | 8715 | 0.110 |
Why?
| | Invasive Pulmonary Aspergillosis | 1 | 2013 | 3 | 0.110 |
Why?
| | Vaccines, Combined | 2 | 2023 | 46 | 0.110 |
Why?
| | Transplantation | 1 | 2013 | 23 | 0.110 |
Why?
| | Daptomycin | 1 | 2013 | 17 | 0.110 |
Why?
| | Rectum | 1 | 2014 | 151 | 0.110 |
Why?
| | Creatine Kinase | 1 | 2013 | 72 | 0.110 |
Why?
| | Global Health | 1 | 2015 | 290 | 0.110 |
Why?
| | Drug Interactions | 2 | 2013 | 347 | 0.100 |
Why?
| | Muscular Diseases | 1 | 2013 | 104 | 0.100 |
Why?
| | Laboratories | 2 | 2021 | 95 | 0.090 |
Why?
| | Child, Preschool | 5 | 2023 | 9164 | 0.090 |
Why?
| | Chemoprevention | 1 | 2011 | 88 | 0.090 |
Why?
| | Vaccination | 3 | 2023 | 1209 | 0.090 |
Why?
| | Graft Rejection | 1 | 2013 | 533 | 0.090 |
Why?
| | Linezolid | 1 | 2010 | 16 | 0.090 |
Why?
| | Sertraline | 1 | 2010 | 26 | 0.090 |
Why?
| | Citalopram | 1 | 2010 | 27 | 0.090 |
Why?
| | Tremor | 1 | 2010 | 45 | 0.090 |
Why?
| | Lung Diseases, Fungal | 1 | 2009 | 13 | 0.080 |
Why?
| | Retrospective Studies | 7 | 2020 | 12615 | 0.080 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 373 | 0.080 |
Why?
| | Hospital Mortality | 2 | 2023 | 779 | 0.080 |
Why?
| | Child | 6 | 2023 | 18537 | 0.080 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 647 | 0.080 |
Why?
| | Sequence Analysis, DNA | 2 | 2024 | 737 | 0.070 |
Why?
| | Killer Cells, Natural | 1 | 2009 | 381 | 0.070 |
Why?
| | T-Lymphocytes | 2 | 2006 | 1758 | 0.070 |
Why?
| | Newspapers as Topic | 1 | 2006 | 10 | 0.070 |
Why?
| | Professional Misconduct | 1 | 2006 | 11 | 0.070 |
Why?
| | Hemorrhagic Disorders | 1 | 2006 | 5 | 0.070 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2006 | 43 | 0.070 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2006 | 23 | 0.070 |
Why?
| | Ethics, Research | 1 | 2006 | 34 | 0.070 |
Why?
| | Drug Antagonism | 1 | 2006 | 8 | 0.070 |
Why?
| | Gene Products, gag | 1 | 2006 | 36 | 0.070 |
Why?
| | Phenytoin | 1 | 2006 | 13 | 0.070 |
Why?
| | Prothrombin Time | 1 | 2006 | 34 | 0.070 |
Why?
| | Vitamin K | 1 | 2006 | 42 | 0.070 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2006 | 118 | 0.070 |
Why?
| | Thrombolytic Therapy | 1 | 2006 | 118 | 0.060 |
Why?
| | Recombination, Genetic | 1 | 2006 | 177 | 0.060 |
Why?
| | Amphotericin B | 1 | 2005 | 32 | 0.060 |
Why?
| | Immunity, Herd | 1 | 2024 | 4 | 0.060 |
Why?
| | Pain | 1 | 2010 | 712 | 0.060 |
Why?
| | Tissue Plasminogen Activator | 1 | 2006 | 228 | 0.060 |
Why?
| | Liposomes | 1 | 2005 | 149 | 0.060 |
Why?
| | Anticonvulsants | 1 | 2006 | 182 | 0.060 |
Why?
| | Antiviral Agents | 2 | 2022 | 651 | 0.060 |
Why?
| | Fibrinolytic Agents | 1 | 2006 | 233 | 0.060 |
Why?
| | Autopsy | 1 | 2003 | 86 | 0.060 |
Why?
| | Time Factors | 4 | 2022 | 6182 | 0.060 |
Why?
| | Prospective Studies | 3 | 2024 | 6276 | 0.060 |
Why?
| | Hodgkin Disease | 1 | 2005 | 118 | 0.060 |
Why?
| | B7-2 Antigen | 1 | 2002 | 25 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 286 | 0.050 |
Why?
| | Receptors, CCR5 | 1 | 2002 | 54 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 12 | 0.050 |
Why?
| | Brain Ischemia | 1 | 2006 | 298 | 0.050 |
Why?
| | Infant | 3 | 2016 | 7992 | 0.050 |
Why?
| | Receptors, CXCR4 | 1 | 2002 | 78 | 0.050 |
Why?
| | Vaccination Coverage | 1 | 2023 | 63 | 0.050 |
Why?
| | Lymphocyte Activation | 1 | 2006 | 1056 | 0.050 |
Why?
| | CD40 Antigens | 1 | 2002 | 80 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2002 | 273 | 0.050 |
Why?
| | HLA-DR Antigens | 1 | 2002 | 220 | 0.050 |
Why?
| | Survival Analysis | 2 | 2016 | 1218 | 0.050 |
Why?
| | Lipopeptides | 2 | 2014 | 14 | 0.050 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2002 | 257 | 0.050 |
Why?
| | Pericardiocentesis | 1 | 2020 | 9 | 0.050 |
Why?
| | Fluconazole | 1 | 2020 | 16 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 433 | 0.050 |
Why?
| | Antigens, CD | 1 | 2002 | 443 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2015 | 1664 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 184 | 0.040 |
Why?
| | Hospitals | 2 | 2015 | 585 | 0.040 |
Why?
| | Prevalence | 1 | 2006 | 2270 | 0.040 |
Why?
| | RNA, Viral | 1 | 2002 | 564 | 0.040 |
Why?
| | Vancomycin | 1 | 2020 | 76 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2196 | 0.040 |
Why?
| | Incidence | 2 | 2016 | 2336 | 0.040 |
Why?
| | Vascular Grafting | 1 | 2018 | 12 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2006 | 3914 | 0.040 |
Why?
| | Cytokines | 1 | 2006 | 1858 | 0.040 |
Why?
| | Endocarditis | 1 | 2018 | 32 | 0.040 |
Why?
| | Echocardiography | 1 | 2020 | 565 | 0.040 |
Why?
| | Patient Readmission | 1 | 2021 | 609 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2002 | 2416 | 0.030 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2015 | 22 | 0.030 |
Why?
| | Patient Isolation | 1 | 2015 | 16 | 0.030 |
Why?
| | Contraindications | 1 | 2015 | 86 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2016 | 5084 | 0.030 |
Why?
| | Developed Countries | 1 | 2015 | 29 | 0.030 |
Why?
| | Body Fluids | 1 | 2015 | 58 | 0.030 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2015 | 26 | 0.030 |
Why?
| | Africa | 1 | 2015 | 99 | 0.030 |
Why?
| | Ebolavirus | 1 | 2015 | 34 | 0.030 |
Why?
| | Equipment Contamination | 1 | 2015 | 55 | 0.030 |
Why?
| | Age Distribution | 1 | 2015 | 341 | 0.030 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2015 | 71 | 0.030 |
Why?
| | Colorado | 2 | 2014 | 4122 | 0.030 |
Why?
| | Diarrhea | 1 | 2015 | 173 | 0.030 |
Why?
| | Travel | 1 | 2015 | 121 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 103 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2014 | 309 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2014 | 156 | 0.030 |
Why?
| | Fluorobenzenes | 1 | 2013 | 11 | 0.030 |
Why?
| | Rosuvastatin Calcium | 1 | 2013 | 17 | 0.030 |
Why?
| | Allografts | 1 | 2013 | 127 | 0.030 |
Why?
| | Feces | 1 | 2015 | 373 | 0.030 |
Why?
| | Simvastatin | 1 | 2013 | 59 | 0.030 |
Why?
| | Dystrophin | 1 | 1992 | 30 | 0.030 |
Why?
| | Muscular Dystrophies | 1 | 1992 | 36 | 0.030 |
Why?
| | Recurrence | 1 | 2015 | 950 | 0.030 |
Why?
| | Neoplasms | 1 | 2006 | 2114 | 0.030 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2014 | 179 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2015 | 525 | 0.020 |
Why?
| | APACHE | 1 | 2011 | 60 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1359 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 5555 | 0.020 |
Why?
| | Anticoagulants | 1 | 2015 | 549 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1476 | 0.020 |
Why?
| | Patient Care Team | 1 | 2015 | 522 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 1863 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1443 | 0.020 |
Why?
| | Risk | 1 | 2013 | 829 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 376 | 0.020 |
Why?
| | Sulfonamides | 1 | 2013 | 447 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 69 | 0.020 |
Why?
| | Postoperative Complications | 2 | 2009 | 2164 | 0.020 |
Why?
| | Mass Screening | 1 | 2015 | 1024 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2015 | 847 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 309 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 140 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1405 | 0.020 |
Why?
| | Los Angeles | 1 | 2006 | 56 | 0.020 |
Why?
| | Brain Damage, Chronic | 1 | 2006 | 19 | 0.020 |
Why?
| | Echo-Planar Imaging | 1 | 2006 | 17 | 0.020 |
Why?
| | Ethics Committees, Research | 1 | 2006 | 38 | 0.020 |
Why?
| | Convalescence | 1 | 2006 | 15 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2006 | 85 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 944 | 0.020 |
Why?
| | Drug Approval | 1 | 2006 | 78 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2006 | 249 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2006 | 295 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 666 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 2006 | 262 | 0.020 |
Why?
| | Risk Assessment | 1 | 2013 | 2992 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 796 | 0.010 |
Why?
| | Research | 1 | 2006 | 398 | 0.010 |
Why?
| | Patient Selection | 1 | 2006 | 655 | 0.010 |
Why?
| | Lung | 1 | 2013 | 3683 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 4960 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2006 | 2590 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2006 | 4443 | 0.010 |
Why?
| | Biomarkers | 1 | 2006 | 3474 | 0.010 |
Why?
| | Brain | 1 | 2006 | 2372 | 0.010 |
Why?
| | DNA Probes | 1 | 1992 | 59 | 0.010 |
Why?
| | X Chromosome | 1 | 1992 | 47 | 0.010 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1992 | 31 | 0.010 |
Why?
| | Sex Chromosome Aberrations | 1 | 1992 | 51 | 0.010 |
Why?
| | Chromosome Deletion | 1 | 1992 | 95 | 0.010 |
Why?
| | Exons | 1 | 1992 | 303 | 0.010 |
Why?
| | Muscles | 1 | 1992 | 328 | 0.010 |
Why?
| | Blotting, Western | 1 | 1992 | 1153 | 0.010 |
Why?
| | Biopsy | 1 | 1992 | 1056 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1992 | 1264 | 0.000 |
Why?
|
|
Barron's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|